Gemcitabine-Based Chemogene Therapy for Pancreatic Cancer Using Ad-dCK::UMK GDEPT and TS/RR siRNA Strategies
Gemcitabine is a first-line agent for advanced pancreatic cancer therapy. However, its efficacy is often limited by its poor intracellular metabolism and chemoresistance. To exert its antitumor activity, gemcitabine requires to be converted to its active triphosphate form. Thus, our aim was to impro...
Main Authors: | Soukaina Réjiba, Christelle Bigand, Céline Parmentier, Amor Hajri |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2009-07-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S147655860980016X |
Similar Items
-
Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement.
by: Soukaina Réjiba, et al.
Published: (2013-01-01) -
Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK
by: Qiaoxian He, et al.
Published: (2024-04-01) -
Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway
by: Darius Stukas, et al.
Published: (2023-08-01) -
Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer
by: Hai Yang, et al.
Published: (2022-06-01) -
Chemogenic processes in the Azov paradynamic landscape system
by: Vorovka V. P.
Published: (2017-01-01)